GMAB Competitors & Alternatives
Compare Genmab AS with similar stocks in the same industry
Biotechnology
GMAB
Main Stock$25.94
Tradestie Score
62
Market Cap
$19.56B
P/E Ratio
19.5
Revenue Growth
0.3%
Analyst Upside
+41.9%
Top Competitors
225 stocks in Biotechnology| Company | Price | Market Cap | P/E | Score | Action |
|---|---|---|---|---|---|
|
INCY
Incyte Genomics Inc
|
$104.40
|
$16.93B | 14.6 | 60 | Compare |
|
RPRX
Royalty Pharma plc Class A Ordinary Shares
|
$55.35
|
$15.70B | 27.9 | 60 | Compare |
|
SMMT
Summit Therapeutics Inc. Common Stock
|
$14.25
|
$15.22B | - | 50 | Compare |
|
ASND
Ascendis Pharma A/S American Depositary Shares
|
$238.59
|
$12.36B | 26.9 | 55 | Compare |
|
EXEL
Exelixis Inc
|
$51.34
|
$11.09B | 17.0 | 60 | Compare |
|
ROIV
Roivant Sciences Ltd. Common Shares
|
$32.21
|
$10.76B | - | 63 | Compare |
|
MRNA
Moderna, Inc. Common Stock
|
$61.00
|
$10.74B | - | 60 | Compare |
|
BMRN
BioMarin Pharmaceuticals Inc
|
$56.50
|
$10.53B | 40.2 | 65 | Compare |
|
IONS
Ionis Pharmaceuticals, Inc. Common Stock
|
$75.99
|
$10.49B | - | 64 | Compare |
|
BBIO
BridgeBio Pharma, Inc. Common Stock
|
$68.63
|
$10.22B | - | 65 | Compare |
More GMAB Analysis
Data updated: Jun 24, 2026 | Industry: Biotechnology (SIC 2834)
225 stocks in this industry